J. N. George and C. M. Nester, Syndromes of thrombotic microangiopathy, N. Engl. J. Med, vol.371, pp.654-666, 2014.

C. Loirat, F. Fakhouri, G. Ariceta, N. Besbas, M. Bitzan et al., An international consensus approach to the management of atypical hemolytic uremic syndrome in children, Pediatr. Nephrol. Berl. Ger, vol.31, pp.15-39, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02149335

M. Scully, S. Cataland, P. Coppo, J. Rubia, K. D. De-la-friedman et al., Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies, J. Thromb. Haemost, vol.15, pp.312-322, 2016.

/. Shigatoxin and . Verocytotoxin, Producing Escherichia coli (STEC/VTEC) Infection-AER, 2016.

C. Gasser, E. Gautier, A. Steck, R. E. Siebenmann, and R. Oechslin, Hemolytic-uremic syndrome: Bilateral necrosis of the renal cortex in acute acquired hemolytic anemia

, Schweiz Med. Wochenschr, vol.85, pp.905-909, 1955.

M. A. Karmali, B. T. Steele, M. Petric, and C. Lim, Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools, Lancet Lond. Engl, vol.1, pp.619-620, 1983.

A. D. O'brien, T. A. Lively, T. W. Chang, and S. L. Gorbach, Purification of Shigella dysenteriae 1 (Shiga)-like toxin from Escherichia coli O157:H7 strain associated with haemorrhagic colitis, Lancet Lond. Engl, vol.2, p.573, 1983.

S. E. Majowicz, E. Scallan, A. Jones-bitton, J. M. Sargeant, J. Stapleton et al., Global incidence of human Shiga toxin-producing Escherichia coli infections and deaths: A systematic review and knowledge synthesis, Foodborne Pathog. Dis, vol.11, pp.447-455, 2014.

C. Frank, D. Werber, J. P. Cramer, M. Askar, M. Faber et al., Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany, N. Engl. J. Med, vol.365, pp.1771-1780, 2011.

T. Butler, Haemolytic uraemic syndrome during shigellosis, Trans. R. Soc. Trop. Med. Hyg, vol.106, pp.395-399, 2012.

M. D. Gray, K. A. Lampel, N. A. Strockbine, R. E. Fernandez, A. R. Melton-celsa et al., Clinical Isolates of Shiga Toxin 1a-Producing Shigella flexneri with an Epidemiological Link to Recent Travel to Hispañiola, Emerg. Infect. Dis. CDC, vol.20, pp.1669-1677, 2014.

M. D. Gray, D. W. Lacher, S. R. Leonard, J. Abbott, S. Zhao et al., Prevalence of Shiga toxin-producing Shigella species isolated from French travellers returning from the Caribbean: An emerging pathogen with international implications, Clin. Microbiol. Infect, vol.21, 2015.
URL : https://hal.archives-ouvertes.fr/pasteur-02044234

K. Lamba, J. A. Nelson, A. C. Kimura, A. Poe, J. Collins et al., Emerg. Infect. Dis. CDC, vol.22, pp.679-686, 2014.

H. Schmidt, M. Montag, J. Bockemühl, J. Heesemann, and H. Karch, Shiga-like toxin II-related cytotoxins in Citrobacter freundii strains from humans and beef samples, Infect. Immun, vol.61, pp.534-543, 1993.

A. R. Constantinescu, M. Bitzan, L. S. Weiss, E. Christen, B. S. Kaplan et al., Non-enteropathic hemolytic uremic syndrome: Causes and short-term course, Am. J. Kidney Dis, vol.43, pp.976-982, 2004.

J. M. Spinale, R. L. Ruebner, B. S. Kaplan, and L. Copelovitch, Update on Streptococcus pneumoniae associated hemolytic uremic syndrome, Curr. Opin. Pediatr, vol.25, pp.203-208, 2013.

L. W. Riley, R. S. Remis, S. D. Helgerson, H. B. Mcgee, J. G. Wells et al., Hemorrhagic colitis associated with a rare Escherichia coli serotype, N. Engl. J. Med, vol.308, pp.681-685, 1983.

W. M. Johnson, H. Lior, and G. S. Bezanson, Cytotoxic Escherichia coli O157:H7 associated with haemorrhagic colitis in Canada, Lancet Lond. Engl, 1983.

B. Swaminathan, P. Gerner-smidt, L. Ng, S. Lukinmaa, K. Kam et al., Building PulseNet International: An interconnected system of laboratory networks to facilitate timely public health recognition and response to foodborne disease outbreaks and emerging foodborne diseases, Foodborne Pathog. Dis, vol.3, pp.36-50, 2006.

M. A. Croxen and B. Finlay, Molecular mechanisms of Escherichia coli pathogenicity, Nat. Rev. Microbiol, vol.8, pp.26-38, 2010.

M. Bielaszewska, A. Mellmann, W. Zhang, R. Köck, A. Fruth et al., Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: A microbiological study, Lancet Infect. Dis, vol.11, pp.671-676, 2011.

P. Boerlin, S. A. Mcewen, F. Boerlin-petzold, J. B. Wilson, R. P. Johnson et al., Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans, J. Clin. Microbiol, vol.37, pp.497-503, 1999.

L. Byrne, G. L. Vanstone, N. T. Perry, N. Launders, G. K. Adak et al., Epidemiology and microbiology of Shiga toxin-producing Escherichia coli other than serogroup O157 in England, J. Med. Microbiol, vol.63, pp.1181-1188, 2009.

M. A. Karmali, M. Mascarenhas, S. Shen, K. Ziebell, S. Johnson et al., Association of genomic O island 122 of Escherichia coli EDL 933 with verocytotoxin-producing Escherichia coli seropathotypes that are linked to epidemic and/or serious disease, J. Clin. Microbiol, vol.41, pp.4930-4940, 2003.

N. Kobayashi, K. Lee, A. Yamazaki, S. Saito, I. Furukawa et al., Virulence gene profiles and population genetic analysis for exploration of pathogenic serogroups of Shiga toxin-producing Escherichia coli, J. Clin. Microbiol, vol.51, pp.4022-4028, 2013.

Y. Ogura, T. Ooka, A. Iguchi, H. Toh, M. Asadulghani et al., Comparative genomics reveal the mechanism of the parallel evolution of O157 and non-O157 enterohemorrhagic Escherichia coli, Proc. Natl. Acad. Sci, vol.106, pp.17939-17944, 2009.

L. M. Wick, W. Qi, D. W. Lacher, and T. S. Whittam, Evolution of genomic content in the stepwise emergence of Escherichia coli O157:H7, J. Bacteriol, vol.187, pp.1783-1791, 2005.

P. Feng, K. A. Lampel, H. Karch, and T. S. Whittam, Genotypic and phenotypic changes in the emergence of Escherichia coli O157:H7, J. Infect. Dis, vol.177, pp.1750-1753, 1998.

J. W. Newland, N. A. Strockbine, S. F. Miller, A. D. O'brien, and R. K. Holmes, Cloning of Shiga-like toxin structural genes from a toxin converting phage of Escherichia coli, Science, vol.230, pp.179-181, 1985.

A. Krüger and P. M. Lucchesi, Shiga toxins and stx phages: Highly diverse entities. Microbiology Read, vol.161, pp.451-462, 2015.

S. A. Mauro and G. B. Koudelka, Shiga toxin: Expression, distribution, and its role in the environment, Toxins, vol.3, pp.608-625, 2011.

A. Krüger, P. M. Lucchesi, and A. E. Parma, Verotoxins in Bovine and Meat Verotoxin-Producing Escherichia coli Isolates: Type, Number of Variants, and Relationship to Cytotoxicity, Appl. Environ. Microbiol, vol.77, pp.73-79, 2011.

P. T. Kimmitt, C. R. Harwood, and M. R. Barer, Toxin gene expression by shiga toxin-producing Escherichia coli: The role of antibiotics and the bacterial SOS response, Emerg. Infect. Dis, vol.6, pp.458-465, 2000.

P. L. Wagner and M. K. Waldor, Bacteriophage control of bacterial virulence, Infect. Immun, vol.70, pp.3985-3993, 2002.

P. L. Wagner, J. Livny, M. N. Neely, D. W. Acheson, D. I. Friedman et al., Bacteriophage control of Shiga toxin 1 production and release by Escherichia coli, Mol. Microbiol, vol.44, pp.957-970, 2002.

P. C. Feng, S. R. Monday, D. W. Lacher, L. Allison, A. Siitonen et al., Genetic diversity among clonal lineages within Escherichia coli O157:H7 stepwise evolutionary model, Emerg. Infect. Dis, vol.13, pp.1701-1706, 2007.

D. Werber, M. Bielaszewska, C. Frank, K. Stark, and H. Karch, Watch out for the even eviler cousin-sorbitol-fermenting E coli O157, Lancet, vol.377, pp.298-299, 2011.

K. Alpers, D. Werber, C. Frank, J. Koch, A. W. Friedrich et al., Sorbitol-fermenting enterohaemorrhagic Escherichia coli O157:H-causes another outbreak of haemolytic uraemic syndrome in children, Epidemiol. Infect, vol.137, pp.389-395, 2009.

A. Ammon, L. R. Petersen, and H. Karch, A large outbreak of hemolytic uremic syndrome caused by an unusual sorbitol-fermenting strain of Escherichia coli O157:H, J. Infect. Dis, vol.179, pp.1274-1277, 1999.

D. Orth, K. Grif, L. B. Zimmerhackl, and R. Würzner, Sorbitol-fermenting Shiga toxin-producing Escherichia coli O157 in Austria, Wien. Klin. Wochenschr, vol.121, pp.108-112, 2009.

L. H. Gould, R. K. Mody, K. L. Ong, P. Clogher, A. B. Cronquist et al., Increased recognition of non-O157 Shiga toxin-producing Escherichia coli infections in the United States during 2000-2010: Epidemiologic features and comparison with E. coli O157 infections, Foodborne Pathog. Dis, vol.10, pp.453-460, 2013.

J. T. Brooks, E. G. Sowers, J. G. Wells, K. D. Greene, P. M. Griffin et al., Non-O157 Shiga Toxin-Producing Escherichia coli Infections in the United States, J. Infect. Dis, vol.192, pp.1422-1429, 1983.

E. B. Hedican, C. Medus, J. M. Besser, B. A. Juni, B. Koziol et al., Characteristics of O157 versus Non-O157 Shiga Toxin-Producing Escherichia coli Infections in Minnesota, 2000.

, Clin. Infect. Dis, vol.49, pp.358-364, 2009.

A. Cointe, A. Birgy, P. Mariani-kurkdjian, S. Liguori, C. Courroux et al., Emerging Multidrug-Resistant Hybrid Pathotype Shiga Toxin-Producing Escherichia coli O80 and Related Strains of Clonal Complex 165, Europe. Emerg. Infect. Dis, vol.24, pp.2262-2269, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02154578

N. Soysal, P. Mariani-kurkdjian, Y. Smail, S. Liguori, M. Gouali et al., Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge, Emerg. Infect. Dis, vol.22, pp.1604-1612, 2016.

P. Mariani-kurkdjian, C. Lemaître, P. Bidet, D. Perez, L. Boggini et al., Haemolytic-uraemic syndrome with bacteraemia caused by a new hybrid Escherichia coli pathotype, New Microbes New Infect, vol.2, pp.127-131, 2014.

L. Fierz, N. Cernela, E. Hauser, M. Nüesch-inderbinen, and R. Stephan, Characteristics of Shigatoxin-Producing Escherichia coli Strains Isolated during 2010-2014 from Human Infections in Switzerland, Front. Microbiol, 1471.

K. L. Wijnsma, A. M. Schijvens, J. W. Rossen, A. M. Kooistra-smid, M. F. Schreuder et al., Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2, Pediatr. Nephrol, vol.32, pp.1263-1268, 2017.

M. Nüesch-inderbinen, N. Cernela, D. Wüthrich, A. Egli, and R. Stephan, Genetic characterization of Shiga toxin producing Escherichia coli belonging to the emerging hybrid pathotype O80:H2 isolated from humans 2010-2017 in Switzerland, Int. J. Med. Microbiol, vol.308, pp.534-538, 2018.

J. L. Hadler, P. Clogher, S. Hurd, Q. Phan, M. Mandour et al., Ten-Year Trends and Risk Factors for Non-O157 Shiga Toxin-Producing Escherichia coli Found Through Shiga Toxin Testing, Clin. Infect. Dis, vol.53, pp.269-276, 2000.

S. A. Braune, D. Wichmann, M. C. Heinz, A. Nierhaus, H. Becker et al., Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome, Crit. Care Med, vol.41, pp.1702-1710, 2013.

D. A. Rasko, D. R. Webster, J. W. Sahl, A. Bashir, N. Boisen et al., Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany, N. Engl. J. Med, vol.365, pp.709-717, 2011.

L. Zimmerhackl, A. Rosales, J. Hofer, M. Riedl, T. Jungraithmayr et al., Enterohemorrhagic Escherichia coli O26:H11-Associated Hemolytic Uremic Syndrome: Bacteriology and Clinical Presentation, Semin. Thromb. Hemost, vol.36, pp.586-593, 2010.

M. Bielaszewska, A. Mellmann, S. Bletz, W. Zhang, R. Köck et al., Enterohemorrhagic Escherichia coli O26:H11/H-: A new virulent clone emerges in Europe, Clin. Infect. Dis, vol.56, pp.1373-1381, 2013.

O. K. Felsenfeld and . Shiga, Bacteriologist. Science, vol.126, 1957.

K. Shiga, Zentralblat Fuer Bakteriol Parasitenkd Infekt Erste Abt, vol.24, pp.913-918, 1898.

L. Johannes and W. Römer, Shiga toxins-From cell biology to biomedical applications, Nat. Rev. Microbiol, vol.8, pp.105-116, 2010.

M. J. Walsh, J. E. Dodd, and G. M. Hautbergue, Ribosome-inactivating proteins: Potent poisons and molecular tools, Virulence, vol.4, pp.774-784, 2013.

H. Ling, A. Boodhoo, B. Hazes, M. D. Cummings, G. D. Armstrong et al., Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3, Biochemistry, vol.37, pp.1777-1788, 1998.

P. E. Stein, A. Boodhoo, G. J. Tyrrell, J. L. Brunton, and R. J. Read, Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli, Nature, vol.355, pp.748-750, 1992.

F. Scheutz, L. D. Teel, L. Beutin, D. Piérard, G. Buvens et al., Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature, J. Clin. Microbiol, vol.50, pp.2951-2963, 2012.

S. M. Ostroff, P. I. Tarr, M. A. Neill, J. H. Lewis, N. Hargrett-bean et al., Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections, J. Infect. Dis, vol.160, pp.994-998, 1989.

A. Matussek, I. Einemo, A. Jogenfors, S. Löfdahl, and S. Löfgren, Shiga Toxin-Producing Escherichia coli in Diarrheal Stool of Swedish Children: Evaluation of Polymerase Chain Reaction Screening and Duration of Shiga Toxin Shedding, J. Pediatr. Infect. Dis. Soc, vol.5, pp.147-151, 2016.

M. Bielaszewska, A. W. Friedrich, T. Aldick, R. Schürk-bulgrin, and H. Karch, Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: Predictor for a severe clinical outcome, Clin. Infect. Dis, vol.43, pp.1160-1167, 2006.

D. Orth, K. Grif, A. B. Khan, A. Naim, M. P. Dierich et al., The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome, Diagn. Microbiol. Infect. Dis, vol.59, pp.235-242, 2007.

L. R. Marques, J. S. Peiris, S. J. Cryz, and A. D. O'brien, Escherichia coli strains isolated from pigs with edema disease produce a variant of Shiga-like toxin II, FEMS Microbiol. Lett, vol.44, pp.33-38, 1987.

H. Schmidt, J. Scheef, S. Morabito, A. Caprioli, L. H. Wieler et al., A new Shiga toxin 2 variant (Stx2f) from Escherichia coli isolated from pigeons, Appl. Environ. Microbiol, vol.66, pp.1205-1208, 2000.

K. Seto, M. Taguchi, K. Kobayashi, and S. Kozaki, Biochemical and molecular characterization of minor serogroups of Shiga toxin-producing Escherichia coli isolated from humans in Osaka prefecture, J. Vet. Med. Sci, vol.69, pp.1215-1222, 2007.

Y. Etoh, K. Murakami, S. Ichihara, N. Sera, M. Hamasaki et al., Isolation of Shiga toxin 2f-producing Escherichia coli (O115:HNM) from an adult symptomatic patient in Fukuoka Prefecture, Japan. Jpn. J. Infect. Dis, vol.62, pp.315-317, 2009.

A. Sonntag, E. Zenner, H. Karch, and M. Bielaszewska, Pigeons as a possible reservoir of Shiga toxin 2f-producing Escherichia coli pathogenic to humans, Berl. Munch. Tierarztl. Wochenschr, vol.118, pp.464-470, 2005.

C. Jenkins, G. A. Willshaw, J. Evans, T. Cheasty, H. Chart et al., Subtyping of virulence genes in verocytotoxin-producing Escherichia coli (VTEC) other than serogroup O157 associated with disease in the United Kingdom, J. Med. Microbiol, vol.52, pp.941-947, 2003.

D. Pierard, L. Huyghens, S. Lauwers, and H. Lior, Diarrhoea associated with Escherichia coli producing porcine oedema disease verotoxin, Lancet Lond. Engl, vol.338, 1991.

I. Friesema, K. Zwaluw, T. Van-der-schuurman, M. Kooistra-smid, E. Franz et al., Emergence of Escherichia coli encoding Shiga toxin 2f in human Shiga toxin-producing E. coli (STEC) infections in the Netherlands, vol.19, 2008.

K. De-rauw, S. Jacobs, and D. Piérard, Twenty-seven years of screening for Shiga toxin-producing Escherichia coli in a university hospital, PLoS ONE, vol.13, 1987.

R. Prager, A. Fruth, U. Siewert, U. Strutz, and H. Tschäpe, Escherichia coli encoding Shiga toxin 2f as an emerging human pathogen, Int. J. Med. Microbiol. IJMM, vol.299, pp.343-353, 2009.

I. D. Ogden, N. F. Hepburn, M. Macrae, N. J. Strachan, D. R. Fenlon et al., Long-term survival of Escherichia coli O157 on pasture following an outbreak associated with sheep at a scout camp, Lett. Appl. Microbiol, vol.34, pp.100-104, 2002.

M. Bielaszewska, J. Janda, K. Bláhová, H. Minaríková, E. Jíková et al., Human Escherichia coli O157:H7 infection associated with the consumption of unpasteurized goat's milk, Epidemiol. Infect, vol.119, pp.299-305, 1997.

D. E. Hoey, L. Sharp, C. Currie, C. A. Lingwood, D. L. Gally et al., Verotoxin 1 binding to intestinal crypt epithelial cells results in localization to lysosomes and abrogation of toxicity, Cell Microbiol, vol.5, pp.85-97, 2003.

P. S. Ekong, M. W. Sanderson, and N. Cernicchiaro, Prevalence and concentration of Escherichia coli O157 in different seasons and cattle types processed in North America: A systematic review and meta-analysis of published research, Prev. Vet. Med, vol.121, pp.74-85, 2015.

M. Bruyand, P. Mariani-kurkdjian, S. L. Hello, L. King, D. V. Cauteren et al., Paediatric haemolytic uraemic syndrome related to Shiga toxin-producing Escherichia coli, an overview of 10 years of surveillance in France, 2007.
URL : https://hal.archives-ouvertes.fr/hal-02153948

R. O. Elder, J. E. Keen, G. R. Siragusa, G. A. Barkocy-gallagher, M. Koohmaraie et al., Correlation of enterohemorrhagic Escherichia coli O157 prevalence in feces, hides, and carcasses of beef cattle during processing, Proc. Natl. Acad. Sci, vol.97, pp.2999-3003, 2000.

S. M. Harris, W. Yue, S. A. Olsen, J. Hu, W. J. Means et al., Salt at concentrations relevant to meat processing enhances Shiga toxin 2 production in Escherichia coli O157:H7, Int. J. Food Microbiol, vol.159, pp.186-192, 2012.

K. D. Munns, L. B. Selinger, K. Stanford, L. Guan, T. R. Callaway et al., Perspectives on super-shedding of Escherichia coli O157:H7 by cattle, Foodborne Pathog. Dis, vol.12, pp.89-103, 2015.

C. Smith-spangler, M. L. Brandeau, G. E. Hunter, J. C. Bavinger, M. Pearson et al., Are organic foods safer or healthier than conventional alternatives: A systematic review, Ann. Intern. Med, vol.157, pp.348-366, 2012.

J. Kim, L. Chui, Y. Wang, J. Shen, and B. Jeon, Expansion of Shiga Toxin-Producing Escherichia coli by Use of Bovine Antibiotic Growth Promoters, Emerg. Infect. Dis, vol.22, pp.802-809, 2016.

S. W. Naylor, D. L. Gally, and J. C. Low, Enterohaemorrhagic E. coli in veterinary medicine, Int. J. Med. Microbiol. IJMM, vol.295, pp.419-441, 2005.

M. Louie, S. Read, L. Louie, K. Ziebell, K. Rahn et al., Molecular typing methods to investigate transmission of Escherichia coli O157:H7 from cattle to humans, Epidemiol. Amp. Infect, vol.123, pp.17-24, 1999.

, Importance of culture confirmation of shiga toxin-producing Escherichia coli infection as illustrated by outbreaks of gastroenteritis-New York and North Carolina, Centers for Disease Control and Prevention (CDC), vol.55, pp.1042-1045, 2005.

M. I. Salvadori, J. M. Sontrop, A. X. Garg, L. M. Moist, R. S. Suri et al., Factors that led to the Walkerton tragedy, Kidney Int

U. Buchholz, H. Bernard, D. Werber, M. M. Böhmer, C. Remschmidt et al., German outbreak of Escherichia coli O104:H4 associated with sprouts, N. Engl. J. Med, vol.365, pp.1763-1770, 2011.

J. M. Rangel, P. H. Sparling, C. Crowe, P. M. Griffin, and D. L. Swerdlow, H7 Outbreaks, vol.157, pp.603-609, 1982.

S. Park, B. Szonyi, R. Gautam, K. Nightingale, J. Anciso et al., Risk Factors for Microbial Contamination in Fruits and Vegetables at the Preharvest Level: A Systematic Review, J. Food Prot, vol.75, pp.2055-2081, 2012.

M. Rivas, I. Chinen, E. Miliwebsky, and M. Masana, Risk Factors for Shiga Toxin-Producing Escherichia coli-Associated Human Diseases

P. D. Frenzen, A. Drake, and F. J. Angulo, Economic cost of illness due to Escherichia coli O157 infections in the United States, J. Food Prot, vol.68, pp.2623-2630, 2005.

J. C. Buzby and T. Roberts, The economics of enteric infections: Human foodborne disease costs, Gastroenterology, vol.136, pp.1851-1862, 2009.

D. M. Williams, S. S. Sreedhar, J. J. Mickell, and J. C. Chan, Acute kidney failure: A pediatric experience over 20 years, Arch. Pediatr. Adolesc. Med, vol.156, pp.893-900, 2002.

C. M. Thorpe, Shiga toxin-producing Escherichia coli infection, Clin. Infect. Dis, vol.38, pp.1298-1303, 2004.

M. Rivas, E. Miliwebsky, I. Chinen, C. D. Roldán, L. Balbi et al., Characterization and epidemiologic subtyping of Shiga toxin-producing Escherichia coli strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina, Foodborne Pathog. Dis, vol.3, pp.88-96, 2006.

E. J. Elliott, R. M. Robins-browne, E. V. O'loughlin, V. Bennett-wood, J. Bourke et al., Nationwide study of haemolytic uraemic syndrome: Clinical, microbiological, and epidemiological features, Arch. Dis. Child, vol.85, pp.125-131, 2001.

H. Vally, G. Hall, A. Dyda, J. Raupach, K. Knope et al., Epidemiology of Shiga toxin producing Escherichia coli in Australia, BMC Public Health, vol.12, 2000.

M. A. Karmali, M. Mascarenhas, M. Petric, L. Dutil, K. Rahn et al., Age-Specific Frequencies of Antibodies to Escherichia coli Verocytotoxins (Shiga Toxins) 1 and 2 among Urban and Rural Populations in Southern Ontario, J. Infect. Dis, vol.188, pp.1724-1729, 2003.

T. Kistemann, S. Zimmer, I. Vågsholm, and Y. Andersson, GIS-supported investigation of human EHEC and cattle VTEC O157 infections in Sweden: Geographical distribution, spatial variation and possible risk factors, Epidemiol. Infect, vol.132, pp.495-505, 2004.

P. M. Griffin and R. V. Tauxe, The Epidemiology of Infections Caused by Escherichia coli O157: H7, Other Enterohemorrhagic, E. coli, and the Associated Hemolytic Uremic Syndrome, Epidemiol. Rev, vol.13, pp.60-98, 1991.

E. M. Nielsen, F. Scheutz, and M. Torpdahl, Continuous Surveillance of Shiga Toxin-Producing Escherichia coli Infections by Pulsed-Field Gel Electrophoresis Shows That Most Infections Are Sporadic, Foodborne Pathog. Dis, vol.3, pp.81-87, 2006.

S. Grisaru, J. P. Midgley, L. A. Hamiwka, A. W. Wade, and S. M. Samuel, Diarrhea-associated hemolytic uremic syndrome in southern Alberta: A long-term single-centre experience, Paediatr. Child Health, vol.16, pp.337-340, 2011.

S. D. Manning, A. S. Motiwala, A. C. Springman, W. Qi, D. W. Lacher et al., Variation in virulence among clades of Escherichia coli O157:H7 associated with disease outbreaks, Proc. Natl. Acad. Sci, vol.105, pp.4868-4873, 2008.

S. Dundas, W. T. Todd, A. I. Stewart, P. S. Murdoch, A. K. Chaudhuri et al., The central Scotland Escherichia coli O157:H7 outbreak: Risk factors for the hemolytic uremic syndrome and death among hospitalized patients, Clin. Infect. Dis, vol.33, pp.923-931, 2001.

L. H. Gould, L. Demma, T. F. Jones, S. Hurd, D. J. Vugia et al., Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, Clin. Infect. Dis, vol.49, pp.1480-1485, 2000.

B. M. Whitney, C. Mainero, E. Humes, S. Hurd, L. Niccolai et al., Socioeconomic Status and Foodborne Pathogens in, Emerg. Infect. Dis, vol.21, pp.1617-1624, 2000.

D. S. Newburg, P. Chaturvedi, E. L. Lopez, S. Devoto, A. Fayad et al., Susceptibility to hemolytic-uremic syndrome relates to erythrocyte glycosphingolipid patterns, J. Infect. Dis, vol.168, pp.476-479, 1993.

S. Watarai, K. Yokota, T. Kishimoto, T. Kanadani, K. Taketa et al., Relationship between susceptibility to hemolytic-uremic syndrome and levels of globotriaosylceramide in human sera, J. Clin. Microbiol, vol.39, pp.798-800, 2001.

A. Taranta, A. Gianviti, A. Palma, V. De-luca, L. Mannucci et al., Genetic risk factors in typical haemolytic uraemic syndrome, Nephrol. Dial. Transplant, vol.24, pp.1851-1857, 2009.

Y. Fujii, S. Numata, Y. Nakamura, T. Honda, K. Furukawa et al., Murine glycosyltransferases responsible for the expression of globo-series glycolipids: cDNA structures, mRNA expression, and distribution of their products, Glycobiology, vol.15, pp.1257-1267, 2005.

J. C. Argyle, R. J. Hogg, T. J. Pysher, F. G. Silva, and R. L. Siegler, A clinicopathological study of 24 children with hemolytic uremic syndrome, Pediatr. Nephrol, vol.4, pp.52-58, 1990.

C. D. Inward, A. J. Howie, M. M. Fitzpatrick, F. Rafaat, D. V. Milford et al., Renal histopathology in fatal cases of diarrhoea-associated haemolytic uraemic syndrome, Pediatr. Nephrol, vol.11, pp.556-559, 1997.

T. R. Keepers, M. A. Psotka, L. K. Gross, and T. G. Obrig, A Murine Model of HUS: Shiga Toxin with Lipopolysaccharide Mimics the Renal Damage and Physiologic Response of Human Disease, J. Am. Soc. Nephrol, vol.17, pp.3404-3414, 2006.

T. R. Keepers, L. K. Gross, and T. G. Obrig, Monocyte Chemoattractant Protein 1, Macrophage Inflammatory Protein 1?, and RANTES Recruit Macrophages to the Kidney in a Mouse Model of Hemolytic-Uremic Syndrome, Infect. Immun, vol.75, pp.1229-1236, 2007.

J. K. Roche, T. R. Keepers, L. K. Gross, R. M. Seaner, and T. G. Obrig, CXCL1/KC and CXCL2/MIP-2 Are Critical Effectors and Potential Targets for Therapy of Escherichia coli O157:H7-Associated Renal Inflammation, Am. J. Pathol, vol.170, pp.526-537, 2007.

C. L. Mayer, C. S. Leibowitz, S. Kurosawa, and D. J. Stearns-kurosawa, Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals, Toxins, vol.4, pp.1261-1287, 2012.

K. L. Mohawk and A. D. O'brien, Mouse models of Escherichia coli O157:H7 infection and shiga toxin injection, J. Biomed. Biotechnol, 2011.

F. Proulx, E. Seidman, M. M. Mariscalco, K. Lee, and S. Caroll, Circulating Levels of Lipopolysaccharide Binding Protein in Children with Escherichia coli O157:H7 Hemorrhagic Colitis and Hemolytic Uremic Syndrome, Clin. Diagn. Lab. Immunol, vol.6, 1999.

F. Koster, J. Levin, L. Walker, K. S. Tung, R. H. Gilman et al., Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes, N. Engl. J. Med, vol.298, pp.927-933, 1978.

S. Dennhardt, W. Pirschel, B. Wissuwa, C. Daniel, F. Gunzer et al., Modeling Hemolytic-Uremic Syndrome: In-Depth Characterization of Distinct Murine Models Reflecting Different Features of Human Disease, Front. Immunol, vol.9, 2018.

C. L. Hews, S. Tran, U. Wegmann, B. Brett, A. D. Walsham et al., The StcE metalloprotease of enterohaemorrhagic Escherichia coli reduces the inner mucus layer and promotes adherence to human colonic epithelium ex vivo, Cell. Microbiol, vol.19, 2017.

T. K. Mcdaniel, K. G. Jarvis, M. S. Donnenberg, and J. B. Kaper, A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens, Proc. Natl. Acad. Sci, vol.92, pp.1664-1668, 1995.

A. L. Erdem, F. Avelino, J. Xicohtencatl-cortes, and J. A. Girón, Host Protein Binding and Adhesive Properties of H6 and H7 Flagella of Attaching and Effacing Escherichia coli, J. Bacteriol, vol.189, pp.7426-7435, 2007.

J. Xicohtencatl-cortes, V. Monteiro-neto, M. A. Ledesma, D. M. Jordan, O. Francetic et al., Intestinal adherence associated with type IV pili of enterohemorrhagic Escherichia coli O157:H7, J. Clin. Investig, vol.117, pp.3519-3529, 2007.

C. M. Robinson, J. F. Sinclair, M. J. Smith, and A. D. O'brien, Shiga toxin of enterohemorrhagic Escherichia coli type O157:H7 promotes intestinal colonization, Proc. Natl. Acad. Sci, vol.103, pp.9667-9672, 2006.

S. M. Weiss, M. Ladwein, D. Schmidt, J. Ehinger, S. Lommel et al., IRSp53 links the enterohemorrhagic E. coli effectors Tir and EspFU for actin pedestal formation, Cell Host Microbe, vol.5, pp.244-258, 2009.

J. Garmendia, A. D. Phillips, M. Carlier, Y. Chong, S. Schüller et al., TccP is an enterohaemorrhagic Escherichia coli O157:H7 type III effector protein that couples Tir to the actin-cytoskeleton, Cell Microbiol, vol.6, pp.1167-1183, 2004.

H. Cheng, B. M. Skehan, K. G. Campellone, J. M. Leong, and M. K. Rosen, Structural mechanism of WASP activation by the enterohaemorrhagic E. coli effector EspF(U), Nature, vol.454, pp.1009-1013, 2008.

O. Kovbasnjuk, R. Mourtazina, B. Baibakov, T. Wang, C. Elowsky et al., The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer, Proc. Natl. Acad. Sci, vol.102, pp.19087-19092, 2005.

S. Schüller, R. Heuschkel, F. Torrente, J. B. Kaper, and A. D. Phillips, Shiga toxin binding in normal and inflamed human intestinal mucosa. Microbes Infect, vol.9, pp.35-39, 2007.

I. Malyukova, K. F. Murray, C. Zhu, E. Boedeker, A. Kane et al., Macropinocytosis in Shiga toxin 1 uptake by human intestinal epithelial cells and transcellular transcytosis, Am. J. Physiol. Gastrointest. Liver Physiol, vol.296, pp.78-92, 2009.

S. Schüller, Shiga Toxin Interaction with Human Intestinal Epithelium, Toxins, vol.3, pp.626-639, 2011.

M. Brigotti, The Interactions of Human Neutrophils with Shiga Toxins and Related Plant Toxins: Danger or Safety? Toxins, vol.4, pp.157-190, 2012.

T. Loo, D. M. Van-hinsbergh, V. W. Van-den, L. P. Heuvel, and L. A. Monnens, Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome, J. Am. Soc. Nephrol. JASN, vol.12, pp.800-806, 2001.

M. Brigotti, A. Caprioli, A. E. Tozzi, P. L. Tazzari, F. Ricci et al., Shiga toxins present in the gut and in the polymorphonuclear leukocytes circulating in the blood of children with hemolytic-uremic syndrome, J. Clin. Microbiol, vol.44, pp.313-317, 2006.

J. M. Geelen, T. J. Van-der-velden, D. M. Loo, O. C. Boerman, . Van-den et al., Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes, Nephrol. Dial. Transplant, vol.22, pp.749-755, 2007.

M. J. Flagler, J. E. Strasser, C. L. Chalk, and A. A. Weiss, Comparative analysis of the abilities of Shiga toxins 1 and 2 to bind to and influence neutrophil apoptosis, Infect. Immun, vol.75, pp.760-765, 2007.

M. Brigotti, D. Carnicelli, E. Ravanelli, S. Barbieri, F. Ricci et al., Interactions between Shiga toxins and human polymorphonuclear leukocytes, J. Leukoc. Biol, vol.84, pp.1019-1027, 2008.

S. E. Richardson, T. A. Rotman, V. Jay, C. R. Smith, L. E. Becker et al., Experimental verocytotoxemia in rabbits, Infect. Immun, vol.60, pp.4154-4167, 1992.

M. Brigotti, P. L. Tazzari, E. Ravanelli, D. Carnicelli, L. Rocchi et al., Clinical relevance of shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome, Pediatr. Infect. Dis. J, vol.30, pp.486-490, 2011.

T. G. Obrig, C. B. Louise, C. A. Lingwood, B. Boyd, L. Barley-maloney et al., Endothelial heterogeneity in Shiga toxin receptors and responses, J. Biol. Chem, vol.268, pp.15484-15488, 1993.

F. Khan, F. Proulx, and C. A. Lingwood, Detergent-resistant globotriaosyl ceramide may define verotoxin/glomeruli-restricted hemolytic uremic syndrome pathology, Kidney Int, vol.75, pp.1209-1216, 2009.

L. L. Cooling, K. E. Walker, T. Gille, and T. A. Koerner, Shiga Toxin Binds Human Platelets via Globotriaosylceramide (Pk Antigen) and a Novel Platelet Glycosphingolipid, Infect. Immun, vol.66, pp.4355-4366, 1998.

M. Mangeney, Y. Richard, D. Coulaud, T. Tursz, and J. Wiels, CD77: An antigen of germinal center B cells entering apoptosis, Eur. J. Immunol, vol.21, pp.1131-1140, 1991.

F. Obata, K. Tohyama, A. D. Bonev, G. L. Kolling, T. R. Keepers et al., Shiga Toxin 2 Affects the Central Nervous System through Receptor Globotriaosylceramide Localized to Neurons, J. Infect. Dis, vol.198, pp.1398-1406, 2008.

T. Okuda, N. Tokuda, S. Numata, M. Ito, M. Ohta et al., Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins, J. Biol. Chem, vol.281, pp.10230-10235, 2006.

W. Römer, L. Berland, V. Chambon, K. Gaus, B. Windschiegl et al., Shiga toxin induces tubular membrane invaginations for its uptake into cells, Nature, vol.450, pp.670-675, 2007.

J. Müthing, C. H. Schweppe, H. Karch, and A. W. Friedrich, Shiga toxins, glycosphingolipid diversity, and endothelial cell injury, Thromb. Haemost, vol.101, pp.252-264, 2009.

M. L. Torgersen, S. U. Lauvrak, and K. Sandvig, The A-subunit of surface-bound Shiga toxin stimulates clathrin-dependent uptake of the toxin, FEBS J, vol.272, pp.4103-4113, 2005.

A. Villysson, A. Tontanahal, and D. Karpman, Microvesicle Involvement in Shiga Toxin-Associated Infection, Toxins, vol.9, 2017.

L. Johannes, R. G. Parton, P. Bassereau, and S. Mayor, Building endocytic pits without clathrin, Nat. Rev. Mol. Cell Biol, vol.16, pp.311-321, 2015.

K. Sandvig, O. Garred, K. Prydz, J. V. Kozlov, S. H. Hansen et al., Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum, Nature, vol.358, pp.510-512, 1992.

O. Garred, E. Dubinina, A. Polesskaya, S. Olsnes, J. Kozlov et al., Role of the disulfide bond in Shiga toxin A-chain for toxin entry into cells, J. Biol. Chem, vol.272, pp.11414-11419, 1997.

Y. Endo, K. Tsurugi, T. Yutsudo, Y. Takeda, T. Ogasawara et al., Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins, Eur. J. Biochem, vol.171, pp.45-50, 1988.

S. Kavaliauskiene, A. B. Dyve-lingelem, T. Skotland, and K. Sandvig, Protection against Shiga Toxins, Toxins, vol.9, p.44, 2017.

S. Mukhopadhyay and A. D. Linstedt, Manganese Blocks Intracellular Trafficking of Shiga Toxin and Protects Against Shiga Toxicosis, Science, vol.335, pp.332-335, 2012.

R. P. Cherla, S. Y. Lee, P. L. Mees, and V. L. Tesh, Shiga toxin 1-induced cytokine production is mediated by MAP kinase pathways and translation initiation factor eIF4E in the macrophage-like THP-1 cell line, J. Leukoc. Biol, vol.79, pp.397-407, 2006.

D. M. Jandhyala, A. Ahluwalia, J. J. Schimmel, A. B. Rogers, J. M. Leong et al., Activation of the Classical Mitogen-Activated Protein Kinases Is Part of the Shiga Toxin-Induced Ribotoxic Stress Response and Contribute to Shiga Toxin-Induced Inflammation, Infect. Immun, vol.84, pp.138-148, 2016.

V. L. Tesh, Activation of cell stress response pathways by Shiga toxins, Cell Microbiol, vol.14, pp.1-9, 2011.

P. A. Van-setten, L. A. Monnens, R. G. Verstraten, . Van-den, L. P. Heuvel et al., Effects of verocytotoxin-1 on nonadherent human monocytes: Binding characteristics, protein synthesis, and induction of cytokine release, Blood, vol.88, pp.174-183, 1996.

B. Ramegowda and V. L. Tesh, Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines, Infect. Immun, vol.64, pp.1173-1180, 1996.

T. Falguières, F. Mallard, C. Baron, D. Hanau, C. Lingwood et al., Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent-resistant membranes, Mol. Biol. Cell, vol.12, pp.2453-2468, 2001.

P. B. Eisenhauer, P. Chaturvedi, R. E. Fine, A. J. Ritchie, J. S. Pober et al., Tumor necrosis factor alpha increases human cerebral endothelial cell Gb3 and sensitivity to Shiga toxin, Infect. Immun, vol.69, pp.1889-1894, 2001.

P. K. Stricklett, A. K. Hughes, and D. E. Kohan, Inhibition of p38 mitogen-activated protein kinase ameliorates cytokine up-regulated shigatoxin-1 toxicity in human brain microvascular endothelial cells, J. Infect. Dis, vol.191, pp.461-471, 2005.

M. K. Stone, G. L. Kolling, M. H. Lindner, and T. G. Obrig, p38 mitogen-activated protein kinase mediates lipopolysaccharide and tumor necrosis factor alpha induction of shiga toxin 2 sensitivity in human umbilical vein endothelial cells, Infect. Immun, vol.76, pp.1115-1121, 2008.

A. Matussek, J. Lauber, A. Bergau, W. Hansen, M. Rohde et al., Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells, Blood, vol.102, pp.1323-1332, 2003.

M. Lee, S. Koo, D. G. Jeong, V. L. Tesh, and . Shiga, Toxins as Multi-Functional Proteins: Induction of Host Cellular Stress Responses, Role in Pathogenesis and Therapeutic Applications, Toxins, vol.8, p.77, 2016.

A. P. Gobert, M. Vareille, A. Glasser, T. Hindré, T. De-sablet et al., Shiga toxin produced by enterohemorrhagic Escherichia coli inhibits PI3K/NF-kappaB signaling pathway in globotriaosylceramide-3-negative human intestinal epithelial cells, J. Immunol, vol.178, pp.8168-8174, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00801237

A. Sellier-leclerc, V. Fremeaux-bacchi, M. Dragon-durey, M. Macher, P. Niaudet et al., Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome, J. Am. Soc. Nephrol. JASN, vol.18, pp.2392-2400, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00409786

M. Noris, J. Caprioli, E. Bresin, C. Mossali, G. Pianetti et al., Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype, Clin. J. Am. Soc. Nephrol. CJASN, vol.5, pp.1844-1859, 2010.

V. Frémeaux-bacchi, E. C. Miller, M. K. Liszewski, L. Strain, J. Blouin et al., Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome, Blood, vol.112, pp.4948-4952, 2008.

V. Fremeaux-bacchi, M. Dragon-durey, J. Blouin, C. Vigneau, D. Kuypers et al., Complement factor I: A susceptibility gene for atypical haemolytic uraemic syndrome, J. Med. Genet, vol.41, 2004.

E. G. De-jorge, C. L. Harris, J. Esparza-gordillo, L. Carreras, E. A. Arranz et al., Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome, Proc. Natl. Acad. Sci, vol.104, pp.240-245, 2007.

M. Dragon-durey, C. Loirat, S. Cloarec, M. Macher, J. Blouin et al., Anti-Factor H Autoantibodies Associated with Atypical Hemolytic Uremic Syndrome, J. Am. Soc. Nephrol, vol.16, pp.555-563, 2005.

M. Noris and G. Remuzzi, Atypical hemolytic-uremic syndrome, N. Engl. J. Med, vol.361, pp.1676-1687, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-02155926

F. Fakhouri, J. Zuber, V. Frémeaux-bacchi, and C. Loirat, Haemolytic uraemic syndrome, Lancet Lond. Engl, vol.390, pp.681-696, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02155934

C. M. Legendre, C. Licht, P. Muus, L. A. Greenbaum, S. Babu et al., Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome, N. Engl. J. Med, vol.368, pp.2169-2181, 2013.

C. Licht, L. A. Greenbaum, P. Muus, S. Babu, C. L. Bedrosian et al., Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies, Kidney Int, vol.87, pp.1061-1073, 2015.

F. Fakhouri, M. Hourmant, J. M. Campistol, S. R. Cataland, M. Espinosa et al., Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial, Am. J. Kidney Dis, vol.68, pp.84-93, 2016.

M. Noris, F. Mescia, and G. Remuzzi, STEC-HUS, atypical HUS and TTP are all diseases of complement activation, Nat. Rev. Nephrol, vol.8, pp.622-633, 2012.

J. M. Thurman, R. Marians, W. Emlen, S. Wood, C. Smith et al., Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome, Clin. J. Am. Soc. Nephrol. CJASN, vol.4, pp.1920-1924, 2009.

A. Ståhl, L. Sartz, and D. Karpman, Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome, Blood, vol.117, pp.5503-5513, 2011.

S. Ge, B. Hertel, S. H. Emden, J. Beneke, J. Menne et al., Microparticle generation and leucocyte death in Shiga toxin-mediated HUS, Nephrol. Dial. Transplant, vol.27, pp.2768-2775, 2012.

D. Orth, A. B. Khan, A. Naim, K. Grif, J. Brockmeyer et al., Shiga toxin activates complement and binds factor H: Evidence for an active role of complement in hemolytic uremic syndrome, J. Immunol, vol.182, pp.6394-6400, 2009.

K. Poolpol, D. Orth-höller, C. Speth, P. F. Zipfel, C. Skerka et al., Interaction of Shiga toxin 2 with complement regulators of the factor H protein family, Mol. Immunol, vol.58, pp.77-84, 2014.

M. Morigi, M. Galbusera, S. Gastoldi, M. Locatelli, S. Buelli et al., Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis, J. Immunol, vol.187, pp.172-180, 2011.

D. Westra, E. B. Volokhina, R. G. Van-der-molen, T. J. Van-der-velden, A. Jeronimus-klaasen et al., Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome, Pediatr. Nephrol, vol.32, pp.297-309, 2017.

B. C. Lee, C. L. Mayer, C. S. Leibowitz, D. J. Stearns-kurosawa, and S. Kurosawa, Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy, Blood, vol.122, pp.803-806, 2013.

S. Porubsky, G. Federico, J. Müthing, R. Jennemann, N. Gretz et al., Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure, J. Pathol, vol.234, pp.120-133, 2014.

C. Zoja, M. Locatelli, C. Pagani, D. Corna, C. Zanchi et al., Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice, J. Immunol, vol.189, pp.3661-3668, 2012.

M. Delvaeye, M. Noris, A. De-vriese, C. T. Esmon, N. L. Esmon et al., Thrombomodulin mutations in atypical hemolytic-uremic syndrome, N. Engl. J. Med, vol.361, pp.345-357, 2009.

J. L. Vincent, B. Francois, I. Zabolotskikh, M. K. Daga, J. B. Lascarrou et al., Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial, JAMA, vol.321, 1993.

T. Honda, S. Ogata, E. Mineo, Y. Nagamori, S. Nakamura et al., A novel strategy for hemolytic uremic syndrome: Successful treatment with thrombomodulin ?, Pediatrics, vol.131, pp.928-933, 2013.

A. K. Hughes, Z. Ergonul, P. K. Stricklett, and D. E. Kohan, Molecular Basis for High Renal Cell Sensitivity to the Cytotoxic Effects of Shigatoxin-1: Upregulation of Globotriaosylceramide Expression, J. Am. Soc. Nephrol, vol.13, pp.2239-2245, 2002.

C. Zoja, S. Buelli, and M. Morigi, Shiga toxin-associated hemolytic uremic syndrome: Pathophysiology of endothelial dysfunction, Pediatr. Nephrol, vol.25, pp.2231-2240, 2010.

T. N. Petruzziello-pellegrini, M. Moslemi-naeini, and P. Marsden, New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome, vol.4, pp.556-563, 2013.

W. L. Chandler, S. Jelacic, D. R. Boster, M. A. Ciol, G. D. Williams et al., Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome, N. Engl. J. Med, vol.346, pp.23-32, 2002.

R. J. Goldberg, T. Nakagawa, R. J. Johnson, and J. M. Thurman, The role of endothelial cell injury in thrombotic microangiopathy, Am. J. Kidney Dis, vol.56, pp.1168-1174, 2010.

T. N. Petruzziello-pellegrini, D. A. Yuen, A. V. Page, S. Patel, A. M. Soltyk et al., The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice, J. Clin. Investig, vol.122, pp.759-776, 2012.

E. Nestoridi, O. Tsukurov, R. I. Kushak, J. R. Ingelfinger, and E. F. Grabowski, Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: Implications for the pathophysiology of hemolytic uremic syndrome*, J. Thromb. Haemost, vol.3, pp.752-762, 2005.

J. Huang, S. L. Haberichter, and J. E. Sadler, The B subunits of Shiga-like toxins induce regulated VWF secretion in a phospholipase D1-dependent manner, Blood, vol.120, pp.1143-1149, 2012.

F. Liu, J. Huang, and J. E. Sadler, Shiga toxin (Stx)1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways, Blood, vol.118, pp.3392-3398, 2011.

D. Karpman, D. Papadopoulou, K. Nilsson, A. C. Sjögren, C. Mikaelsson et al., Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome, Blood, vol.97, pp.3100-3108, 2001.

M. Morigi, G. Micheletti, M. Figliuzzi, B. Imberti, M. A. Karmali et al., Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions, Blood, vol.86, pp.4553-4558, 1995.

C. Zoja, S. Angioletti, R. Donadelli, C. Zanchi, S. Tomasoni et al., Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1, Kidney Int, vol.62, pp.846-856, 2002.

A. H. Pijpers, P. A. Van-setten, . Van-den, L. P. Heuvel, K. J. Assmann et al., Verocytotoxin-induced apoptosis of human microvascular endothelial cells, J. Am. Soc. Nephrol. JASN, vol.12, pp.767-778, 2001.

D. Karpman, A. Håkansson, M. T. Perez, C. Isaksson, E. Carlemalm et al., Apoptosis of renal cortical cells in the hemolytic-uremic syndrome: In vivo and in vitro studies, Infect. Immun, vol.66, pp.636-644, 1998.

A. P. Owens and N. Mackman, Tissue factor and thrombosis: The clot starts here, Thromb. Haemost, vol.104, pp.432-439, 2010.

I. Arvidsson, A. Ståhl, M. M. Hedström, A. Kristoffersson, C. Rylander et al., Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome, J. Immunol, vol.194, pp.2309-2318, 2015.

P. Clogher, S. Hurd, D. Hoefer, J. L. Hadler, L. Pasutti et al., Assessment of physician knowledge and practices concerning Shiga toxin-producing Escherichia coli infection and enteric illness, Foodborne Diseases Active Surveillance Network (FoodNet), vol.2012, pp.446-452, 2009.

P. I. Tarr, C. A. Gordon, and W. L. Chandler, Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome, Lancet, vol.365, pp.1073-1086, 2005.

G. Reiss, P. Kunz, D. Koin, and E. B. Keeffe, Escherichia coli O157:H7 infection in nursing homes: Review of literature and report of recent outbreak, J. Am. Geriatr. Soc, vol.54, pp.680-684, 2006.

A. O. Carter, A. A. Borczyk, J. A. Carlson, B. Harvey, J. C. Hockin et al., A severe outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home, N. Engl. J. Med, vol.317, pp.1496-1500, 1987.

M. A. Mcdonough and J. R. Butterton, Spontaneous tandem amplification and deletion of the Shiga toxin operon in Shigella dysenteriae 1, Mol. Microbiol, vol.34, pp.1058-1069, 1999.

R. K. Mody, W. Gu, P. M. Griffin, T. F. Jones, J. Rounds et al., Postdiarrheal hemolytic uremic syndrome in United States children: Clinical spectrum and predictors of in-hospital death, J. Pediatr, vol.166, pp.1022-1029, 2015.

L. H. Gould, Update: Recommendations for Diagnosis of Shiga Toxin-Producing Escherichia coli Infections by Clinical Laboratories, Clin. Microbiol. Newsl, vol.34, pp.75-83, 2012.

R. K. Mody, R. E. Luna-gierke, T. F. Jones, N. Comstock, S. Hurd et al., Infections in pediatric postdiarrheal hemolytic uremic syndrome: Factors associated with identifying shiga toxin-producing Escherichia coli, Arch. Pediatr. Adolesc. Med, vol.166, pp.902-909, 2012.

C. S. Wong, J. C. Mooney, J. R. Brandt, A. O. Staples, S. Jelacic et al., Risk Factors for the Hemolytic Uremic Syndrome in Children Infected With Escherichia coli O157:H7: A Multivariable Analysis, Clin. Infect. Dis, vol.55, pp.33-41, 2012.

L. A. King, F. Nogareda, F. Weill, P. Mariani-kurkdjian, E. Loukiadis et al., Outbreak of Shiga toxin-producing Escherichia coli O104:H4 associated with organic fenugreek sprouts, Clin. Infect. Dis, vol.54, pp.1588-1594, 2011.
URL : https://hal.archives-ouvertes.fr/pasteur-01118497

A. W. Paton, R. M. Ratcliff, R. M. Doyle, J. Seymour-murray, D. Davos et al., Molecular microbiological investigation of an outbreak of hemolytic-uremic syndrome caused by dry fermented sausage contaminated with Shiga-like toxin-producing Escherichia coli, J. Clin. Microbiol, vol.34, pp.1622-1627, 1996.

J. Tuttle, T. Gomez, M. P. Doyle, J. G. Wells, T. Zhao et al., Lessons from a large outbreak of Escherichia coli O157:H7 infections: Insights into the infectious dose and method of widespread contamination of hamburger patties, Epidemiol. Infect, vol.122, pp.185-192, 1999.

W. E. Keene, J. M. Mcanulty, F. C. Hoesly, L. P. Williams, K. Hedberg et al., A swimming-associated outbreak of hemorrhagic colitis caused by Escherichia coli O157:H7 and Shigella sonnei, N. Engl. J. Med, vol.331, pp.579-584, 1994.

H. Fukushima, T. Hashizume, Y. Morita, J. Tanaka, K. Azuma et al., Clinical experiences in Sakai City Hospital during the massive outbreak of enterohemorrhagic Escherichia coli O157 infections in Sakai City, Pediatr. Int, vol.41, pp.213-217, 1996.

P. I. Tarr, Shiga toxin-associated hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Distinct mechanisms of pathogenesis, Kidney Int, vol.75, pp.29-32, 2009.

R. C. Rahman, C. J. Cobeñas, R. Drut, O. R. Amoreo, J. D. Ruscasso et al., Hemorrhagic colitis in postdiarrheal hemolytic uremic syndrome: Retrospective analysis of 54 children, Pediatr. Nephrol, vol.27, pp.229-233, 2012.

A. S. De-buys-roessingh, P. De-lagausie, V. Baudoin, C. Loirat, and Y. Aigrain, Gastrointestinal Complications of Post-Diarrheal Hemolytic Uremic Syndrome, Eur. J. Pediatr. Surg, vol.17, pp.328-334, 2007.

S. M. Ostroff, J. M. Kobayashi, and J. H. Lewis, Infections with Escherichia coli 0157:H7 in Washington State: The First Year of Statewide Disease Surveillance, JAMA, vol.262, pp.355-359, 1989.

J. A. Ake, S. Jelacic, M. A. Ciol, S. L. Watkins, K. F. Murray et al., Relative Nephroprotection During Escherichia coli O157:H7 Infections: Association With Intravenous Volume Expansion, Pediatrics, vol.115, pp.673-680, 2005.

A. Balestracci, S. M. Martin, I. Toledo, C. Alvarado, and R. E. Wainsztein, Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children, Pediatr. Nephrol, vol.27, pp.1407-1410, 2012.

K. Ikeda, O. Ida, K. Kimoto, T. Takatorige, N. Nakanishi et al., Predictors for the development of haemolytic uraemic syndrome with Escherichia coli O157:H7 infections: With focus on the day of illness, Epidemiol. Infect, vol.124, pp.343-349, 2000.

A. Zoufaly, J. P. Cramer, E. Vettorazzi, F. Sayk, J. P. Bremer et al., Risk Factors for Development of Hemolytic Uremic Syndrome in a Cohort of Adult Patients with STEC 0104:H4 Infection, PLoS ONE, vol.8, 2013.

B. Tserenpuntsag, H. Chang, P. F. Smith, and D. L. Morse, Hemolytic Uremic Syndrome Risk and Escherichia coli O157:H7. Emerg, Infect. Dis, vol.11, pp.1955-1957, 2005.

B. P. Bell, P. M. Griffin, P. Lozano, D. L. Christie, J. M. Kobayashi et al., Predictors of Hemolytic Uremic Syndrome in Children During a Large Outbreak of Escherichia coli O157:H7 Infections, Pediatrics, vol.100, 1997.

R. L. Siegler, M. K. Milligan, T. H. Burningham, R. D. Christofferson, S. Y. Chang et al., Long-term outcome and prognostic indicators in the hemolytic-uremic syndrome, J. Pediatr, vol.118, pp.195-200, 1991.

A. Gerber, H. Karch, F. Allerberger, H. M. Verweyen, and L. B. Zimmerhackl, Clinical Course and the Role of Shiga Toxin-Producing Escherichia coli Infection in the Hemolytic-Uremic Syndrome in Pediatric Patients, Germany and Austria: A Prospective Study, vol.186, pp.493-500, 1997.

R. S. Oakes, J. K. Kirkhamm, R. D. Nelson, and R. L. Siegler, Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome, Pediatr. Nephrol, vol.23, pp.1303-1308, 2008.

A. Rosales, J. Hofer, L. Zimmerhackl, T. C. Jungraithmayr, M. Riedl et al., Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae, Clin. Infect. Dis, vol.54, pp.1413-1421, 2012.

A. Lukasz, J. Beneke, J. Menne, F. Vetter, B. M. Schmidt et al., Serum neutrophil gelatinase-associated lipocalin (NGAL) in patients with Shiga toxin mediated haemolytic uraemic syndrome (STEC-HUS), Thromb. Haemost, vol.111, pp.365-372, 2014.

H. Trachtman, C. Austin, M. Lewinski, and R. A. Stahl, Renal and neurological involvement in typical Shiga toxin-associated HUS, Nat. Rev. Nephrol, vol.8, pp.658-669, 2012.

R. S. Oakes, R. L. Siegler, M. A. Mcreynolds, T. Pysher, and A. T. Pavia, Predictors of Fatality in Postdiarrheal Hemolytic Uremic Syndrome, Pediatrics, vol.117, pp.1656-1662, 2006.

T. Magnus, J. Röther, O. Simova, M. Meier-cillien, J. Repenthin et al., The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak, Brain, vol.135, pp.1850-1859, 2012.

K. J. Eriksson, S. G. Boyd, and R. C. Tasker, Acute neurology and neurophysiology of haemolytic-uraemic syndrome, Arch. Dis. Child, vol.84, pp.434-435, 2001.

S. Nathanson, T. Kwon, M. Elmaleh, M. Charbit, E. A. Launay et al., Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome, Clin. J. Am. Soc. Nephrol. CJASN, vol.5, pp.1218-1228, 2010.

N. Cimolai, B. J. Morrison, and J. E. Carter, Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome, Pediatrics, vol.90, pp.616-621, 1992.

A. Kleimann, S. Toto, C. K. Eberlein, J. T. Kielstein, S. Bleich et al., Psychiatric symptoms in patients with Shiga toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome, PLoS ONE, vol.9, 2014.

F. Donnerstag, X. Ding, L. Pape, E. Bültmann, T. Lücke et al., Patterns in early diffusion-weighted MRI in children with haemolytic uraemic syndrome and CNS involvement, Eur. Radiol, vol.22, pp.506-513, 2012.

K. Weissenborn, F. Donnerstag, J. T. Kielstein, M. Heeren, H. Worthmann et al., Neurologic manifestations of E coli infection-induced hemolytic-uremic syndrome in adults, Neurology, vol.79, pp.1466-1473, 2012.

N. J. Thomas, J. J. Messina, W. J. Debruin, and J. A. Carcillo, Cardiac failure in hemolytic uremic syndrome and rescue with extracorporeal life support, Pediatr. Cardiol, vol.26, pp.104-106, 2005.

G. E. Gallo and C. A. Gianantonio, Extrarenal involvement in diarrhoea-associated haemolytic-uraemic syndrome, Pediatr. Nephrol, vol.9, pp.117-119, 1995.

R. L. Siegler, R. D. Christofferson, M. K. Milligan, and A. T. Pavia, A 20-Year Population-Based Study of Postdiarrheal Hemolytic Uremic Syndrome in Utah, Pediatrics, vol.94, pp.35-40, 1994.

G. R. Jenssen, L. Vold, E. Hovland, H. Bangstad, K. Nygård et al., Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: A nationwide retrospective study from, BMC Infect. Dis, vol.16, p.285, 1999.

M. Thayu, W. L. Chandler, S. Jelacic, C. A. Gordon, G. L. Rosenthal et al., Cardiac ischemia during hemolytic uremic syndrome, Pediatr. Nephrol, vol.18, pp.286-289, 2003.

J. Mohammed, G. Filler, A. Price, and A. P. Sharma, Cardiac tamponade in diarrhoea-positive haemolytic uraemic syndrome, Nephrol. Dial. Transplant, vol.24, pp.679-681, 2009.

R. S. Suri, W. F. Clark, N. Barrowman, J. L. Mahon, H. R. Thiessen-philbrook et al., Diabetes during diarrhea-associated hemolytic uremic syndrome: A systematic review and meta-analysis, Diabetes Care, vol.28, pp.2556-2562, 2005.

R. S. Suri, J. L. Mahon, W. F. Clark, L. M. Moist, M. Salvadori et al., Relationship between Escherichia coli O157:H7 and diabetes mellitus, Kidney Int. Suppl, vol.75, pp.44-46, 2009.

S. Grodinsky, A. Telmesani, W. L. Robson, G. Fick, and R. B. Scott, Gastrointestinal manifestations of hemolytic uremic syndrome: Recognition of pancreatitis, J. Pediatr. Gastroenterol. Nutr, vol.11, pp.518-524, 1990.

C. Caillaud, A. Zaloszyc, C. Licht, V. Pichault, V. Frémeaux-bacchi et al., CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS), Pediatr. Nephrol, vol.31, pp.157-161, 2016.

R. L. Siegler, P. M. Griffin, T. J. Barrett, and N. A. Strockbine, Recurrent Hemolytic Uremic Syndrome Secondary to Escherichia coli 0157:H7 Infection, Pediatrics, vol.91, pp.666-668, 1993.

M. Commereuc, F. Weill, E. Loukiadis, M. Gouali, A. Gleizal et al., Recurrent Hemolytic and Uremic Syndrome Induced by Escherichia Coli, Medicine, vol.95, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01317405

G. Buvens, K. De-rauw, S. Roisin, G. Vanfraechem, O. Denis et al., Verocytotoxin-producing Escherichia coli O128ab:H2 bacteremia in a 27-year-old male with hemolytic-uremic syndrome, J. Clin. Microbiol, vol.51, pp.1633-1635, 2013.

C. Chiurchiu, A. Firrincieli, M. Santostefano, M. Fusaroli, G. Remuzzi et al., Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection, Am. J. Kidney Dis, vol.41, 2003.

T. Lienemann, E. Salo, R. Rimhanen-finne, K. Rönnholm, M. Taimisto et al., Shiga toxin-producing Escherichia coli serotype O78:H(-) in family, Emerg. Infect. Dis, vol.18, pp.577-581, 2009.

Q. Nguyen, L. Hochstrasser, C. Chuard, H. Hächler, C. Regamey et al., Adult hemolytic-uremic syndrome associated with urosepsis due to Shigatoxin-producing Escherichia coli O138:H, Ren. Fail, vol.29, pp.747-750, 2007.

M. Starr, V. Bennett-wood, A. K. Bigham, T. F. De-koning-ward, A. M. Bordun et al., Hemolytic-uremic syndrome following urinary tract infection with enterohemorrhagic Escherichia coli: Case report and review, Clin. Infect. Dis, vol.27, pp.310-315, 1998.

S. Bonacorsi, O. Clermont, V. Houdouin, C. Cordevant, N. Brahimi et al., Molecular analysis and experimental virulence of French and North American Escherichia coli neonatal meningitis isolates: Identification of a new virulent clone, J. Infect. Dis, vol.187, pp.1895-1906, 2003.

C. Peigne, P. Bidet, F. Mahjoub-messai, C. Plainvert, V. Barbe et al., The plasmid of Escherichia coli strain S88 (O45:K1:H7) that causes neonatal meningitis is closely related to avian pathogenic E. coli plasmids and is associated with high-level bacteremia in a neonatal rat meningitis model, Infect. Immun, vol.77, pp.2272-2284, 2009.

C. J. Cobeñas, P. S. Bresso, L. L. Lombardi, O. R. Amoreo, J. D. Ruscasso et al., Relationship between red blood cell transfusion requirements and severity of renal disease during the acute stage of hemolytic uremic syndrome, Pediatr. Nephrol, vol.30, pp.2115-2119, 2015.

L. Pape, T. Ahlenstiel, M. Kreuzer, J. Drube, K. Froede et al., Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome-A randomized prospective pilot trial, Pediatr. Nephrol, vol.24, pp.1061-1064, 2009.

A. Balestracci, S. M. Martin, I. Toledo, C. Alvarado, and R. E. Wainsztein, Early erythropoietin in post-diarrheal hemolytic uremic syndrome: A case-control study, Pediatr. Nephrol, vol.30, pp.339-344, 2015.

H. Trachtman, A. Cnaan, E. Christen, K. Gibbs, S. Zhao et al., Effect of an Oral Shiga Toxin-Binding Agent on Diarrhea-Associated Hemolytic Uremic Syndrome in Children: A Randomized Controlled Trial, JAMA, vol.290, pp.1337-1344, 2003.

C. Nadon, I. Van-walle, P. Gerner-smidt, J. Campos, I. Chinen et al., PulseNet International: Vision for the implementation of whole genome sequencing (WGS) for global food-borne disease surveillance, vol.22, 2017.

A. C. Voetsch, F. J. Angulo, T. Rabatsky-ehr, S. Shallow, M. Cassidy et al., Laboratory Practices for Stool-Specimen Culture for Bacterial Pathogens, Including Escherichia coli O157:H7, in the FoodNet Sites, Clin. Infect. Dis, vol.38, pp.190-197, 1995.

P. I. Tarr, M. A. Neill, C. R. Clausen, S. L. Watkins, D. L. Christie et al., Escherichia coli O157:H7 and the hemolytic uremic syndrome: Importance of early cultures in establishing the etiology, J. Infect. Dis, vol.162, pp.553-556, 1990.

N. A. Cornick, S. Jelacic, M. A. Ciol, and P. I. Tarr, Escherichia coli O157:H7 infections: Discordance between filterable fecal shiga toxin and disease outcome, J. Infect. Dis, vol.186, pp.57-63, 2002.

S. B. March and S. Ratnam, Sorbitol-MacConkey medium for detection of Escherichia coli O157:H7 associated with hemorrhagic colitis, J. Clin. Microbiol, vol.23, pp.869-872, 1986.

H. S. Hussein and L. M. Bollinger, Influence of Selective Media on Successful Detection of Shiga Toxin-Producing Escherichia coli in Food, Fecal, and Environmental Samples, Foodborne Pathog. Dis, vol.5, pp.227-244, 2008.

K. A. Bettelheim, H. Evangelidis, J. L. Pearce, E. Sowers, and N. A. Strockbine, Isolation of a Citrobacter freundii strain which carries the Escherichia coli O157 antigen, J. Clin. Microbiol, vol.31, pp.760-761, 1993.

N. Zelyas, A. Poon, L. Patterson-fortin, R. P. Johnson, W. Lee et al., Assessment of commercial chromogenic solid media for the detection of non-O157 Shiga toxin-producing Escherichia coli (STEC)

, Diagn. Microbiol. Infect. Dis, vol.85, pp.302-308, 2016.

K. G. Pollock, M. E. Locking, T. J. Beattie, H. Maxwell, I. Ramage et al., Sorbitol-fermenting Escherichia coli O157, Scotland. Emerg. Infect. Dis, vol.16, pp.881-882, 2010.

K. L. Wijnsma, S. A. Van-bommel, T. Van-der-velden, E. Volokhina, M. F. Schreuder et al., Fecal diagnostics in combination with serology: Best test to establish STEC-HUS, Pediatr. Nephrol, vol.31, pp.2163-2170, 2016.

E. Vallières, M. Saint-jean, and F. Rallu, Comparison of Three Different Methods for Detection of Shiga Toxin-Producing Escherichia coli in a Tertiary Pediatric Care Center, J. Clin. Microbiol, vol.51, pp.481-486, 2013.

M. Bielaszewska, R. Prager, R. Köck, A. Mellmann, W. Zhang et al., Shiga Toxin Gene Loss and Transfer In Vitro and In Vivo during Enterohemorrhagic Escherichia coli O26 Infection in Humans, Appl. Environ. Microbiol, vol.73, pp.3144-3150, 2007.

M. Bielaszewska, R. Köck, A. W. Friedrich, C. Von-eiff, L. B. Zimmerhackl et al., Shiga Toxin-Mediated Hemolytic Uremic Syndrome: Time to Change the Diagnostic Paradigm?, PLoS ONE, vol.2, 1024.

, Scientific Opinion on VTEC-seropathotype and scientific criteria regarding pathogenicity assessment, EFSA J, vol.3138, issue.11, 2013.

V. K. Sharma and E. A. Dean-nystrom, Detection of enterohemorrhagic Escherichia coli O157:H7 by using a multiplex real-time PCR assay for genes encoding intimin and Shiga toxins, Vet. Microbiol, vol.93, pp.247-260, 2003.

A. Holmes, L. Allison, M. Ward, T. J. Dallman, R. Clark et al., Utility of Whole-Genome Sequencing of Escherichia coli O157 for Outbreak Detection and Epidemiological Surveillance, J. Clin. Microbiol, vol.53, pp.3565-3573, 2015.

K. G. Joensen, A. M. Tetzschner, A. Iguchi, F. M. Aarestrup, and F. Scheutz, Rapid and Easy In Silico Serotyping of Escherichia coli Isolates by Use of Whole-Genome Sequencing Data, J. Clin. Microbiol, vol.53, pp.2410-2426, 2015.

Z. Zhou, N. Alikhan, K. Mohamed, M. Achtman, and Y. Fan, The Agama Study Group. The user's guide to comparative genomics with EnteroBase. Three case studies: Micro-clades within Salmonella enterica serovar Agama, ancient and modern populations of Yersinia pestis, and core genomic diversity of all Escherichia, vol.10, 2019.

H. Karch, M. Bielaszewska, M. Bitzan, and H. Schmidt, Epidemiology and diagnosis of Shiga toxin-producing Escherichia coli infections, Diagn. Microbiol. Infect. Dis, vol.34, pp.229-243, 1999.

L. Chui, L. Patterson-fortin, J. Kuo, V. Li, and V. Boras, Evaluation of enzyme immunoassays and real-time PCR for detecting Shiga toxin-producing Escherichia coli in Southern Alberta, Canada. J. Clin. Microbiol, vol.53, pp.1019-1023, 2015.

X. Qin, E. J. Klein, E. Galanakis, A. A. Thomas, J. R. Stapp et al., Real-Time PCR Assay for Detection and Differentiation of Shiga Toxin-Producing Escherichia coli from Clinical Samples, J. Clin. Microbiol, vol.53, pp.2148-2153, 2015.

H. Chart, N. T. Perry, T. Cheasty, and P. A. Wright, The kinetics of antibody production to antigens of Escherichia coli O157 in a pregnant woman with haemolytic uraemic syndrome, J. Med. Microbiol, vol.51, pp.522-525, 2002.

H. Chart and C. Jenkins, The serodiagnosis of infections caused by Verocytotoxin-producing Escherichia coli, J. Appl. Microbiol, vol.86, pp.731-740, 1999.

L. R. Holtz, M. A. Neill, and P. I. Tarr, Acute bloody diarrhea: A medical emergency for patients of all ages, Gastroenterology, vol.136, pp.1887-1898, 2009.

J. M. Trotter, L. Hunt, and M. B. Peter, Ischaemic colitis, BMJ, vol.355, p.6600, 2016.

F. H. Miller, J. J. Ma, and F. J. Scholz, Imaging Features of Enterohemorrhagic Escherichia coli Colitis, Am. J. Roentgenol, vol.177, pp.619-623, 2001.

A. Joseph, C. Rafat, L. Zafrani, P. Mariani-kurkdjian, A. Veyradier et al., Early Differentiation of Shiga Toxin-Associated Hemolytic Uremic Syndrome in Critically Ill Adults With Thrombotic Microangiopathy Syndromes, Crit. Care Med, vol.46, pp.904-911, 2018.

P. Coppo, M. Schwarzinger, M. Buffet, A. Wynckel, K. Clabault et al., Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: The French TMA reference center experience, PLoS ONE, vol.5, 2010.

M. J. Bentley, C. M. Lehman, R. C. Blaylock, A. R. Wilson, and G. M. Rodgers, The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange, Transfusion, vol.50, pp.1654-1664, 2010.

P. M. Mannucci and M. Cugno, The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring, Thromb. Res, vol.136, pp.851-854, 2015.

S. R. Cataland and H. M. Wu, How I treat: The clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome, Blood, vol.123, pp.2478-2484, 2014.

P. K. Bendapudi, S. Hurwitz, A. Fry, M. B. Marques, S. W. Waldo et al., Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: A cohort study, Lancet Haematol, vol.4, pp.157-164, 2017.

R. I. Ejemot, J. E. Ehiri, M. M. Meremikwu, and J. A. Critchley, Hand washing for preventing diarrhoea, Cochrane Database Syst. Rev, vol.004265, 2008.

, The Five Keys to Safer Food Programme, p.20, 2020.

A. Ahmed, J. Li, Y. Shiloach, J. B. Robbins, and S. C. Szu, Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children, J. Infect. Dis, vol.193, pp.515-521, 2006.

M. J. Smith, L. D. Teel, H. M. Carvalho, A. R. Melton-celsa, and A. D. O'brien, Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine, vol.24, pp.4122-4129, 2006.

S. X. Wen, L. D. Teel, N. A. Judge, and A. D. O'brien, A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2, Proc. Natl. Acad. Sci, vol.103, pp.7082-7087, 2006.

X. Gao, K. Cai, J. Shi, H. Liu, X. Hou et al., Immunogenicity of a novel Stx2B-Stx1B fusion protein in a mice model of Enterohemorrhagic Escherichia coli O157:H7 infection, vol.27, pp.2070-2076, 2009.

L. V. Bentancor, M. Bilen, R. J. Brando, M. V. Ramos, L. C. Ferreira et al., A DNA Vaccine Encoding the Enterohemorragic Escherichia coli Shiga-Like Toxin 2 A2 and B Subunits Confers Protective Immunity to Shiga Toxin Challenge in the Murine Model, Clin. Vaccine Immunol, vol.16, pp.712-718, 2009.

S. C. Szu and A. Ahmed, Clinical Studies of Escherichia coli O157:H7 Conjugate Vaccines in Adults and Young Children, Microbiol. Spectr, vol.2, 2014.

D. E. Thomas and E. J. Elliott, Interventions for preventing diarrhea-associated hemolytic uremic syndrome: Systematic review, BMC Public Health, vol.13, 2013.

N. P. Varela, P. Dick, and J. Wilson, Assessing the existing information on the efficacy of bovine vaccination against Escherichia coli O157:H7-A systematic review and meta-analysis, vol.60, pp.253-268, 2013.

J. M. Sargeant, M. R. Amezcua, A. Rajic, and L. Waddell, Pre-harvest Interventions to Reduce the Shedding of E. coli O157 in the Faeces of Weaned Domestic Ruminants: A Systematic Review, Zoonoses Public Health, vol.54, pp.260-277, 2007.

T. R. Callaway, R. O. Elder, J. E. Keen, R. C. Anderson, and D. J. Nisbet, Forage Feeding to Reduce Preharvest Escherichia coli Populations in Cattle, a Review, J. Dairy Sci, vol.86, pp.852-860, 2003.

J. Ellis-iversen, R. P. Smith, S. V. Winden, G. A. Paiba, E. Watson et al., Farm practices to control E. coli O157 in young cattle-A randomised controlled trial, Vet. Res, vol.39, pp.3-12, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00902893

E. D. Berry and J. E. Wells, Soil Solarization Reduces Escherichia coli O157:H7 and Total Escherichia coli on Cattle Feedlot Pen Surfaces, J. Food Prot, vol.75, pp.7-13, 2012.

E. and S. Available-online, , p.20, 2020.

D. Werber, B. W. Mason, M. R. Evans, and R. L. Salmon, Preventing household transmission of Shiga toxin-producing Escherichia coli O157 infection: Promptly separating siblings might be the key, Clin. Infect. Dis, vol.46, pp.1189-1196, 2008.

, Shiga Toxin-Producing Escherichia coli: Guidance, Data and Analysis-GOV.UK. Available online, p.20, 2020.

M. Mor and S. Ashkenazi, The dilemma of antimicrobial treatment of Shiga toxin-producing Escherichia coli, Pediatr. Infect. Dis. J, vol.33, pp.979-981, 2014.

M. L. Bennish, W. A. Khan, M. Begum, E. A. Bridges, S. Ahmed et al., Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh, Clin. Infect. Dis, vol.42, pp.356-362, 2006.

C. S. Wong, S. Jelacic, R. L. Habeeb, S. L. Watkins, and P. I. Tarr, The Risk of the Hemolytic-Uremic Syndrome after Antibiotic Treatment of Escherichia coli O157:H7 Infections, N. Engl. J. Med, vol.342, pp.1930-1936, 2000.

K. Ikeda, O. Ida, K. Kimoto, T. Takatorige, N. Nakanishi et al., Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection, Clin. Nephrol, vol.52, pp.357-362, 1999.

H. Tajiri, J. Nishi, K. Ushijima, T. Shimizu, T. Ishige et al., A role for fosfomycin treatment in children for prevention of haemolytic-uraemic syndrome accompanying Shiga toxin-producing Escherichia coli infection, Int. J. Antimicrob. Agents, vol.5, pp.586-589, 2015.

M. Nitschke, F. Sayk, C. Härtel, R. T. Roseland, S. Hauswaldt et al., Association Between Azithromycin Therapy and Duration of Bacterial Shedding Among Patients With Shiga Toxin-Producing Enteroaggregative Escherichia coli O104:H4, JAMA, vol.307, pp.1046-1052, 2012.

J. Menne, M. Nitschke, R. Stingele, M. Abu-tair, J. Beneke et al., Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: Case-control study, BMJ, vol.345, 2012.

G. Z. Panos, G. I. Betsi, and M. E. Falagas, Systematic review: Are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection?, Aliment. Pharmacol. Ther, vol.24, pp.731-742, 2006.

N. Safdar, A. Said, R. E. Gangnon, and D. G. Maki, Risk of Hemolytic Uremic Syndrome After Antibiotic Treatment of Escherichia coli O157:H7 Enteritis: A Meta-analysis, JAMA, vol.288, pp.996-1001, 2002.

S. B. Freedman, J. Xie, M. S. Neufeld, W. L. Hamilton, L. Hartling et al., Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis, Clin. Infect. Dis, vol.62, pp.1251-1258, 2016.

F. Proulx, J. P. Turgeon, G. Delage, L. Lafleur, and L. Chicoine, Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis, J. Pediatr, vol.121, pp.299-303, 1992.

T. J. Ochoa, J. Chen, C. M. Walker, E. Gonzales, and T. G. Cleary, Rifaximin Does Not Induce Toxin Production or Phage-Mediated Lysis of Shiga Toxin-Producing Escherichia coli, Antimicrob. Agents Chemother, vol.51, pp.2837-2841, 2007.

X. Zhang, A. D. Mcdaniel, L. E. Wolf, G. T. Keusch, M. K. Waldor et al., Quinolone Antibiotics Induce Shiga Toxin-Encoding Bacteriophages, Toxin Production, and Death in Mice, J. Infect. Dis, vol.181, pp.664-670, 2000.

Q. Zhang, A. Donohou-rolfe, G. Krautz-peterson, M. Sevo, N. Parry et al., Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection, J. Infect. Dis, vol.199, pp.486-493, 2009.

K. Grif, M. P. Dierich, H. Karch, and F. Allerberger, Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents, Eur. J. Clin. Microbiol. Infect. Dis, vol.17, pp.761-766, 1998.

K. E. Smith, P. R. Wilker, P. L. Reiter, E. B. Hedican, J. B. Bender et al., Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Pediatr. Infect. Dis. J, vol.31, pp.37-41, 2012.

M. Agger, F. Scheutz, S. Villumsen, K. Mølbak, and A. M. Petersen, Antibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: A systematic review and a proposal, J. Antimicrob. Chemother, vol.70, pp.2440-2446, 2015.

, HCSP. Gastroentérites à Escherichia coli Entérohémorragique. Conduite à Tenir

. Haut-conseil-de-la-santé-publique, , p.20, 2015.

T. Garashi, S. Ito, M. Sako, A. Saitoh, H. Hataya et al., Guidelines for the management and investigation of hemolytic uremic syndrome, Clin. Exp. Nephrol, vol.18, pp.525-557, 2014.

, Shiga Toxin-Producing Escherichia coli (STEC): Symptoms, How to Avoid, p.20, 2020.

A. L. Shane, R. K. Mody, J. A. Crump, P. I. Tarr, T. S. Steiner et al., Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea, Clin. Infect. Dis, vol.65, 2017.

J. M. Nelson, P. M. Griffin, T. F. Jones, K. E. Smith, and E. Scallan, Antimicrobial and antimotility agent use in persons with shiga toxin-producing Escherichia coli O157 infection in FoodNet Sites, Clin. Infect. Dis, vol.52, pp.1130-1132, 2011.

S. Grisaru, J. Xie, S. Samuel, L. Hartling, P. I. Tarr et al., Alberta Provincial Pediatric Enteric Infection Team. Associations Between Hydration Status, Intravenous Fluid Administration, and Outcomes of Patients Infected With Shiga Toxin-Producing Escherichia coli: A Systematic Review and Meta-analysis, JAMA Pediatr, vol.171, pp.68-76, 2017.

G. Ardissino, F. Tel, I. Possenti, S. Testa, D. Consonni et al., Early Volume Expansion and Outcomes of Hemolytic Uremic Syndrome, Pediatrics, vol.137, 2016.

S. Lüth, T. W. Fründt, T. Rösch, C. Schlee, and A. W. Lohse, Prevention of hemolytic uremic syndrome with daily bowel lavage in patients with Shiga toxin-producing enterohemorrhagic Escherichia coli O104:H4 infection, JAMA Intern. Med, vol.174, pp.1003-1005, 2014.

J. A. Kellum, N. Lameire, P. Aspelin, R. S. Barsoum, E. A. Burdmann et al., Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury, Kidney Int, vol.2, pp.1-138

N. M. Mehta, H. E. Skillman, S. Y. Irving, J. A. Coss-bu, S. Vermilyea et al., Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Pediatric Critically Ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition, JPEN J. Parenter. Enter. Nutr, vol.41, pp.706-742, 2017.

R. Blaser, A. Starkopf, J. Alhazzani, W. Berger, M. M. Casaer et al., Early enteral nutrition in critically ill patients: ESICM clinical practice guidelines, Intensive Care Med, vol.43, pp.380-398, 2017.

R. O. Mathew, A. Nayer, and A. Asif, The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy, J. Am. Soc. Hypertens. JASH, vol.10, pp.352-359, 2016.

C. Gómez-lado, F. Martinón-torres, A. Alvarez-moreno, J. Eirís-puñal, N. Carreira-sande et al., Reversible posterior leukoencephalopathy syndrome: An infrequent complication in the course of haemolytic-uremic syndrome, Rev. Neurol, vol.44, pp.475-478, 2007.

M. V. Dyck and W. Proesmans, Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome, Pediatr. Nephrol, vol.19, pp.688-690, 2004.

T. K. Davis, T. Neumayr, K. Geile, A. Doctor, and P. Hmeil, Citrate anticoagulation during continuous renal replacement therapy in pediatric critical care, Pediatr. Crit. Care Med, vol.15, pp.471-485, 2014.

S. Morabito, V. Pistolesi, L. Tritapepe, and E. Fiaccadori, Regional citrate anticoagulation for RRTs in critically ill patients with AKI, Clin. J. Am. Soc. Nephrol. CJASN, vol.9, pp.2173-2188, 2014.

J. L. Carson, G. Guyatt, N. M. Heddle, B. J. Grossman, C. S. Cohn et al., Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage, JAMA, vol.316, pp.2025-2035, 2016.

R. Goel, P. M. Ness, C. M. Takemoto, L. Krishnamurti, K. E. King et al., Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality, Blood, vol.125, pp.1470-1476, 2015.

Y. Benhamou, J. Baudel, A. Wynckel, L. Galicier, E. Azoulay et al., Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center, Am. J. Hematol, vol.90, pp.127-129, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02469680

S. M. Duffy and T. E. Coyle, Platelet transfusions and bleeding complications associated with plasma exchange catheter placement in patients with presumed thrombotic thrombocytopenic purpura, J. Clin. Apher, vol.28, pp.356-358, 2013.

A. Balestracci, S. M. Martin, I. Toledo, C. Alvarado, and R. E. Wainsztein, Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome, Pediatr. Nephrol, vol.28, pp.919-925, 2013.

J. Beneke, A. Sartison, J. T. Kielstein, H. Haller, M. Nitschke et al., Clinical and Laboratory Consequences of Platelet Transfusion in Shiga Toxin-Mediated Hemolytic Uremic Syndrome, Transfus. Med. Rev, vol.31, pp.51-55, 2017.

B. R. Weil, S. P. Andreoli, and D. F. Billmire, Bleeding risk for surgical dialysis procedures in children with hemolytic uremic syndrome, Pediatr. Nephrol, vol.25, pp.1693-1698, 2010.

N. Cimolai, S. Basalyga, D. G. Mah, B. J. Morrison, and J. E. Carter, A continuing assessment of risk factors for the development of Escherichia coli O157:H7-associated hemolytic uremic syndrome, Clin. Nephrol, vol.42, pp.85-89, 1994.

A. Guarino, S. Ashkenazi, D. Gendrel, A. Lo-vecchio, R. Shamir et al., European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: Update, J. Pediatr. Gastroenterol. Nutr, vol.59, pp.132-152, 2014.

C. Loirat, E. Sonsino, N. Hinglais, J. P. Jais, P. Landais et al., Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology, Pediatr. Nephrol, vol.2, pp.279-285, 1988.

G. Rizzoni, A. Claris-appiani, A. Edefonti, P. Facchin, F. Franchini et al., Plasma infusion for hemolytic-uremic syndrome in children: Results of a multicenter controlled trial, J. Pediatr, vol.112, pp.284-290, 1988.

G. A. Rock, K. H. Shumak, N. A. Buskard, V. S. Blanchette, J. G. Kelton et al., Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic Purpura, N. Engl. J. Med, vol.325, pp.393-397, 1991.

S. Dundas, J. Murphy, R. L. Soutar, G. A. Jones, S. J. Hutchinson et al., Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak, Lancet, vol.354, pp.1327-1330, 1999.

E. Colic, H. Dieperink, K. Titlestad, and M. Tepel, Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: An observational study, Lancet, vol.378, pp.1089-1093, 2011.

A. Greinacher, S. Friesecke, P. Abel, A. Dressel, S. Stracke et al., Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: A prospective trial, Lancet Lond. Engl, vol.378, pp.1166-1173, 2011.

J. Schwartz, A. Padmanabhan, N. Aqui, R. A. Balogun, L. Connelly-smith et al., Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue, J. Clin. Apher, vol.31, pp.149-162, 2016.

A. Lapeyraque, M. Malina, V. Fremeaux-bacchi, T. Boppel, M. Kirschfink et al., Eculizumab in severe Shiga-toxin-associated HUS, N. Engl. J. Med, vol.364, pp.2561-2563, 2011.

J. T. Kielstein, G. Beutel, S. Fleig, J. Steinhoff, T. N. Meyer et al., Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: An analysis of the German STEC-HUS registry, Nephrol. Dial. Transplant, vol.27, pp.3807-3815, 2012.

Y. Delmas, B. Vendrely, B. Clouzeau, H. Bachir, H. Bui et al., Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: Outcome with eculizumab, Nephrol. Dial. Transplant, vol.29, pp.565-572, 2014.

L. Pape, H. Hartmann, F. C. Bange, S. Suerbaum, and E. Bueltmann, Ahlenstiel-Grunow, T. Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement, vol.94, 1000.

M. Watanabe-takahashi, T. Sato, T. Dohi, N. Noguchi, F. Kano et al., An Orally Applicable Shiga Toxin Neutralizer Functions in the Intestine to Inhibit the Intracellular Transport of the Toxin, Infect. Immun, vol.78, pp.177-183, 2010.

K. Nishikawa, M. Watanabe, E. Kita, K. Igai, K. Omata et al., A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin, FASEB J, vol.20, pp.2597-2599, 2006.

K. Tsutsuki, M. Watanabe-takahashi, Y. Takenaka, E. Kita, and K. Nishikawa, Identification of a Peptide-Based Neutralizer That Potently Inhibits Both Shiga Toxins 1 and 2 by Targeting Specific Receptor-Binding Regions, Infect. Immun, vol.81, pp.2133-2138, 2013.

K. Nishikawa, K. Matsuoka, E. Kita, N. Okabe, M. Mizuguchi et al., A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7, Proc. Natl. Acad. Sci, vol.99, pp.7669-7674, 2002.

P. I. Kitov, J. M. Sadowska, G. Mulvey, G. D. Armstrong, H. Ling et al., Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands, Nature, vol.403, pp.669-672, 2000.

R. A. Bernedo-navarro, M. M. Miyachiro, M. S. Da, C. F. Reis, R. A. Conceição et al., Peptides derived from phage display libraries as potential neutralizers of Shiga toxin-induced cytotoxicity in vitro and in vivo, J. Appl. Microbiol, vol.116, pp.1322-1333, 2014.

T. Li, W. Tu, Y. Liu, P. Zhou, K. Cai et al., A potential therapeutic peptide-based neutralizer that potently inhibits Shiga toxin 2 in vitro and in vivo, Sci. Rep, 2016.

G. L. Mulvey, P. Marcato, P. I. Kitov, J. Sadowska, D. R. Bundle et al., Assessment in Mice of the Therapeutic Potential of Tailored, Multivalent Shiga Toxin Carbohydrate Ligands, J. Infect. Dis, vol.187, pp.640-649, 2003.

A. W. Paton, R. Morona, and J. C. Paton, A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans, Nat. Med, vol.6, pp.265-270, 2000.

S. J. Hostetter, A. F. Helgerson, J. C. Paton, A. W. Paton, and N. A. Cornick, Therapeutic use of a receptor mimic probiotic reduces intestinal Shiga toxin levels in a piglet model of hemolytic uremic syndrome, BMC Res. Notes, vol.7, p.331, 2014.

R. A. Moxley, D. H. Francis, M. Tamura, D. B. Marx, K. Santiago-mateo et al., Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model, Toxins, vol.9, p.49, 2017.

E. L. López, M. M. Contrini, E. Glatstein, S. González-ayala, R. Santoro et al., Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli, Antimicrob. Agents Chemother, vol.54, pp.239-243, 2010.

M. Bitzan, R. Poole, M. Mehran, E. Sicard, C. Brockus et al., Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers, Antimicrob. Agents Chemother, vol.53, pp.3081-3087, 2009.

J. M. Tremblay, J. Mukherjee, C. E. Leysath, M. Debatis, K. Ofori et al., A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2, Infect. Immun, vol.81, pp.4592-4603, 2013.

M. P. Mejías, Y. Hiriart, C. Lauché, R. J. Fernández-brando, R. Pardo et al., Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS)

M. A. Gaston, C. A. Pellino, and A. A. Weiss, Failure of Manganese to Protect from Shiga Toxin, PLoS ONE, vol.8, 2013.

N. Perez, F. Spizzirri, R. Rahman, A. Suarez, C. Larrubia et al., Steroids in the hemolytic uremic syndrome, Pediatr. Nephrol, vol.12, pp.101-104, 1998.

C. Loirat, F. Beaufils, E. Sonsino, N. Schlegel, M. Guesnu et al., Treatment of childhood hemolytic-uremic syndrome with urokinase. Cooperative controlled trial, Arch. Fr. Pediatr, vol.41, pp.15-19, 1984.

J. M. Bergstein, J. R. Edson, and A. F. Michael, Fibrinolytic treatment of the haemolytic-uraemic syndrome, Lancet, vol.1, pp.448-449, 1972.

R. Van-damme-lombaerts, W. Proesmans, B. Van-damme, R. Eeckels, P. Binda-ki-muaka et al., Heparin plus dipyridamole in childhood hemolytic-uremic syndrome: A prospective, randomized study, J. Pediatr, vol.113, pp.913-918, 1988.

C. J. Cobeñas, L. F. Alconcher, A. P. Spizzirri, and R. C. Rahman, Long-term follow-up of Argentinean patients with hemolytic uremic syndrome who had not undergone dialysis, Pediatr. Nephrol, vol.22, pp.1343-1347, 2007.

A. Schieppati, P. Ruggenenti, R. P. Cornejo, F. Ferrario, G. Gregorini et al., Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome, J. Am. Soc. Nephrol. JASN, vol.2, pp.1640-1644, 1992.

J. M. Spinale, R. L. Ruebner, L. Copelovitch, and B. S. Kaplan, Long-term outcomes of Shiga toxin hemolytic uremic syndrome, Pediatr. Nephrol, vol.28, pp.2097-2105, 2013.

A. X. Garg, R. S. Suri, N. Barrowman, F. Rehman, D. Matsell et al., Long-term Renal Prognosis of Diarrhea-Associated Hemolytic Uremic Syndrome: A Systematic Review, Meta-analysis, and Meta-regression, JAMA, vol.290, pp.1360-1370, 2003.

A. X. Garg, M. Salvadori, J. M. Okell, H. R. Thiessen-philbrook, R. S. Suri et al., Albuminuria and estimated GFR 5 years after Escherichia coli O157 hemolytic uremic syndrome: An update, Am. J. Kidney Dis, vol.51, pp.435-444, 2008.

S. Loos, W. Aulbert, B. Hoppe, T. Ahlenstiel-grunow, B. Kranz et al., Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4, Clin. Infect. Dis, vol.64, pp.1637-1643, 2017.

I. Derad, B. Obermann, A. Katalinic, N. Eisemann, J. K. Knobloch et al., Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults, Nephrol. Dial. Transplant, vol.31, pp.95-103, 2016.

H. A. Repetto, Long-term course and mechanisms of progression of renal disease in hemolytic uremic syndrome, Kidney Int. Suppl, vol.68, pp.102-106, 2005.

M. G. Caletti, G. Gallo, and C. A. Gianantonio, Development of focal segmental sclerosis and hyalinosis in hemolytic uremic syndrome, Pediatr. Nephrol, vol.10, pp.687-692, 1996.

L. J. Lo, A. S. Go, G. M. Chertow, C. E. Mcculloch, D. Fan et al., Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease, Kidney Int, vol.76, pp.893-899, 2009.

M. G. Caletti, H. Lejarraga, D. Kelmansky, and M. Missoni, Two different therapeutic regimes in patients with sequelae of hemolytic-uremic syndrome, Pediatr. Nephrol, vol.19, pp.1148-1152, 2004.

M. G. Caletti, M. Missoni, C. Vezzani, M. Grignoli, J. J. Piantanida et al., Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy, Pediatr. Nephrol, vol.26, pp.1247-1254, 2011.

M. Alberti, E. Valoti, R. Piras, E. Bresin, M. Galbusera et al., Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations, Am. J. Transplant, vol.13, pp.2201-2206, 2013.

C. E. Bassani, J. Ferraris, C. A. Gianantonio, S. Ruiz, and J. Ramirez, Renal transplantation in patients with classical haemolytic-uraemic syndrome, Pediatr. Nephrol, vol.5, pp.607-611, 1991.

J. R. Ferraris, J. A. Ramirez, S. Ruiz, M. G. Caletti, G. Vallejo et al., Shiga toxin-associated hemolytic uremic syndrome: Absence of recurrence after renal transplantation, Pediatr. Nephrol, vol.17, pp.809-814, 2002.

C. Loirat and P. Niaudet, The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children, Pediatr. Nephrol, vol.18, pp.1095-1101, 2003.

A. Schlieper, E. Orrbine, G. A. Wells, M. Clulow, P. N. Mclaine et al., Neuropsychological sequelae of haemolytic uraemic syndrome. Investigators of the HUS Cognitive Study, Arch. Dis. Child, vol.80, pp.214-220, 1999.

K. Buder, B. Latal, S. Nef, T. J. Neuhaus, G. F. Laube et al., Neurodevelopmental long-term outcome in children after hemolytic uremic syndrome, Pediatr. Nephrol, vol.30, pp.503-513, 2015.

R. Schuppner, J. Maehlmann, M. Dirks, H. Worthmann, A. B. Tryc et al., H4 Infection-Induced Hemolytic-Uremic Syndrome, vol.104, 2016.

K. Masumoto, Y. Nishimoto, T. Taguchi, Y. Tsutsumi, S. Kanemitsu et al., Colonic stricture secondary to hemolytic uremic syndrome caused by Escherichia coli O-157, Pediatr. Nephrol, vol.20, pp.1496-1499, 2005.

F. D. Spizzirri, R. C. Rahman, N. Bibiloni, J. D. Ruscasso, and O. R. Amoreo, Childhood hemolytic uremic syndrome in Argentina: Long-term follow-up and prognostic features, Pediatr. Nephrol, vol.11, pp.156-160, 1997.

G. Small, A. R. Watson, J. H. Evans, and J. Gallagher, Hemolytic uremic syndrome: Defining the need for long-term follow-up, Clin. Nephrol, vol.52, pp.352-356, 1999.

D. Hüseman, J. Gellermann, I. Vollmer, I. Ohde, S. Devaux et al., Long-term prognosis of hemolytic uremic syndrome and effective renal plasma flow, Pediatr. Nephrol, vol.13, pp.672-677, 1999.

E. L. Lopez, S. Devoto, A. Fayad, C. Canepa, A. L. Morrow et al., Association between severity of gastrointestinal prodrome and long-term prognosis in classic hemolytic-uremic syndrome, J. Pediatr, vol.120, pp.210-215, 1992.

, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, © 2020 by the authors. Licensee MDPI